TargetBeta
SRC
SRC proto-oncogene, non-receptor tyrosine kinase · also ASV, c-src, SRC1 · SH2 domain containing
3 programs in company-led studies act on SRC, from 3 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tirbanibulinrule | Almirall | phase 4 | 122 running | – | ChEMBL |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 93 running | ALK, CD74, NTRK1, NTRK2, NTRK3, PTK2, ROS1, SDC4 | NCIt |
| SRC/YES1 Kinase Inhibitor NXP900rule | Nuvectis Pharma | phase 1 | 33 running | YES1 | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Dermatitis, Phototoxic, 1 program
- Keratosis, Actinic, 1 program
- Lymphoma, 1 program
- Lymphoma, Follicular, 1 program
- Neoplasm Metastasis, 1 program
- Prostatic Neoplasms, 1 program
- Psoriasis, 1 program
- Sarcoma, 1 program
- Warts, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026SRC/YES1 Kinase Inhibitor NXP900 · Nuvectis Pharma · phase 1 · NCT07315113
- Feb 16, 2027repotrectinib · Bristol-Myers Squibb · phase 3 · NCT06140836
- Jul 2027tirbanibulin · Almirall · phase 4 · NCT05387525
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.